5,6-Dimethylxanthenone-4-Acetic Acid (DMXAA) in the Treatment of Refractory Tumors: A Phase I Multicentre Doubleblind Randomized Six-Way Intrapatient Dose-Ranging Crossover Safety Study.

Antisoma Research0 个研究点目标入组 15 人开始时间: 2003年5月1日最近更新: 2009年3月5日

适应症

试验速览

阶段: 1 期
状态: 已完成
发起方
入组人数: 15
主要终点: To identify a range of doses for DMXAA where there was either no effect or an acceptably small effect on QTc

研究概览研究设计入排标准结局指标研究者记录与标识符相似试验

研究概览

简要总结

This was a phase I study aimed at identifying safe doses of DMXAA (now known as ASA404) to be used in future combination studies with chemotherapy.

详细描述

This was a multi-centre randomized, double blind study to further characterize the effect of DMXAA on QTc interval, ophthalmic safety and pharmacodynamic effects on tumour blood flow.

Patients with refractory tumors were to each undergo six doses of treatment at weekly intervals, receiving each of six doses of DMXAA (300, 600, 1200, 1800, 2400 and 3000 mg/m2)

研究设计

研究类型: Interventional
分配方式: Randomized
干预模型: Crossover
主要目的: Treatment
盲法: Double (Participant, Investigator)

入排标准

年龄范围: 18 Years 至 —（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

•Evidence of cancer, by histopathology or cytology, which was not amenable to any standard therapy or was refractory to conventional therapy
•Age ≥ 18 years
•Life expectancy of at least 12 weeks
•WHO performance status of 0-2
•Hematological and biochemical indices at the start of treatment:
•Hemoglobin at least 9 g/dl
•Leukocyte count at least 3.0 x 109/l
•Neutrophils at least 1.5 x 109/l
•Platelets at least 100 x 109/l
•Serum Creatinine not higher than140 μmol/l
•Liver function tests (ALT, AST, ALK PHOS) no higher than thrice the upper limit of the reference range, if no demonstrable liver metastases or no more than 5 x upper limit of the normal range in the presence of liver or bone metastases
•Absolute QTc interval values of less than 470 ms in females and less than 450 ms in males as assessed by the Investigator
•Presence of a lesion which was amenable to dynamic MRI
•Written informed consent and the ability of the patient to co-operate with treatment and follow up

排除标准

•Radiotherapy (except for palliative reasons), endocrine therapy, immunotherapy or chemotherapy during the previous four weeks prior to treatment
•Pregnant or lactating women were excluded
•Patients who were poor medical risks because of non-malignant systemic disease, as well as those with active uncontrolled infection
•Current malignancies at other sites
•Significant history of recreational drug abuse
•Glucocorticosteroids in doses exceeding those required for physiological replacement within the previous 2 weeks
•Skin lesions that may prevent long-term ECG acquisition
•Body mass index above 30 kg/m2
•Patients who were taking certain medications
•Patients with clinical evidence of brain metastases
•Patients with certain cardiac conditions
•Advancing or unstable ischemic heart disease
•Pacing devices and/or implantable cardiovertor-defibrillator
•Significant cardiovascular disease or any unstable cardiovascular disease
•Non-sustained or sustained atrial and/or ventricular tachyarrhythmias
•Atrial fibrillation (including paroxysmal atrial fibrillation) or atrial flutter
•Bundle Branch Block, any stable intra-cardiac conduction abnormality with QRS complex > 120 ms, any unstable intra-cardiac conduction abnormality
•Sick sinus syndrome, or sinus pauses > 2 seconds
•Known atrial and/or ventricular ectopic beats > 10/hour
•Fixed second degree AV block, transient or fixed third degree AV block
•History of documented ventricular flutter, ventricular fibrillation, Torsade de Pointes tachycardia
•Patients who had previously received anthracyclines or other known cardiotoxic medication
•Women with breast implants as these may have interfered with the recording of the ECG
•Patients with severe electrolyte abnormalities and patients in whom transient electrolyte abnormalities may have been expected during any visit of the study
•Patients in whom concomitant neurotropic drug therapy was known to change or was likely to change during the course of the study, where such therapy was likely to affect the patients ERG measurement
•Ophthalmic conditions where in the opinion of the investigator they might affect the recording of the ERG

结局指标

主要结局

To identify a range of doses for DMXAA where there was either no effect or an acceptably small effect on QTc

次要结局

To investigate and describe the relationship between QTc prolongation, plasma levels of DMXAA and time from start of infusion.
To further investigate the safety profile of DMXAA
To further investigate the pharmacokinetic behaviour of DMXAA
To further characterise the ophthalmic effects of DMXAA
To document anti-tumour activity and/or clinical signs of efficacy in patients
To assess the effects of DMXAA on tumour blood flow using dynamic MRI

研究者

发起方

Antisoma Research

申办方类型

Industry

相似试验

已完成

1 期

Study of DMXAA (Now Known as ASA404) in Solid TumorsSolid Tumors

NCT00863733Cancer Research UK63

撤回

1 期

ASA404 in Combination With Carboplatin/Paclitaxel/Cetuximab in Treating Patients With Refractory Solid TumorsTumors

NCT01031212University of California, San Francisco

已完成

1 期

Phase II Study of DMXAA (ASA404) in Combination With Chemotherapy in Patients With Advanced Non-Small Cell Lung CancerNon-Small Cell Lung Cancer

NCT00832494Antisoma Research105

已完成

2 期

A Dose-Ranging Study of the Safety and Efficacy of ADX415 in the Treatment of Essential HypertensionHypertension

NCT00779181Addrenex Pharmaceuticals, Inc.80

进行中（未招募）

1 期

Study of ADXS-504 Immunotherapy for Recurrent Prostate CancerRecurrent Prostate Cancer

NCT05077098Mark Stein8